Comparison of the Efficacy and Safety of Standard versus High Dose Tigecycline

• Published in: International journal of infectious diseases 2022-03, Vol.116, p.S12-S12
• Main Authors: Aljedaani, H., Thabit, A., Eljaaly, K., Aljefri, D., Alotabi, N., Alghamdi, L., Alsahafi, G., Abuzaid, S.
• Format: Article
• Language: English
• ISSN: 1201-9712; 1878-3511
• DOI: 10.1016/j.ijid.2021.12.029

Tigecycline is a broad-spectrum antibiotic usually used as a last resort for infections caused by multidrug-resistant and extensively drug-resistant Gram-negative bacteria, such as Enterobacterales and Acinetobacter spp. The evolvement of antimicrobial resistance has led to the increased demand for tigecycline. However, data comparing the efficacy and safety of high (HD) versus standard doses (SD) of tigecycline are limited. Therefore, this study aimed to compare the clinical and microbiological outcomes of these doses in hospitalized patients. This was a retrospective cohort multicenter study. Adult patients admitted between January 2018 and October 2020 who received tigecycline as monotherapy or in combination with other antibiotics for at least 3 days with a microbiologically documented infection were included. Clinical cure was the primary endpoint. Secondary endpoints included microbiological cure, mortality and length of stay. Of 292 patients, 77 were in the HD group while 215 were in the SD group. Baseline characteristics were similar, except for the duration of tigecycline therapy, which was 3 days longer in the HD group (P= 0.007), and source of infection (P